Coya Therapeutics, Inc. (COYA) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Coya Therapeutics, Inc. (COYA) stock forecast summary
Our AI ranks Coya Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Coya Therapeutics, Inc. is a small-cap company with a market capitalization of $102M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For COYA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 2.0%, measured on 322 forecast dates between 2023-03-31 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 5.0%, measured on 365 forecast dates between 2023-03-31 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.6%, buy ≥ +3.2%, sell < +1.9%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, COYA included.
Follow COYA freeCOYA price chart and AI forecast
How COYA ranks among 5121 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Coya Therapeutics, Inc. (COYA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | COYA | Rank |
|---|---|---|
| Market Cap | $102M | 60/60 |
| P/B Ratio | 2.35x | 39/42 |
| EPS | $-1.19 | – |
| Book Value/Share | $1.84 | – |
| Revenue/Share | $0.34 | – |
Profitability & Margins
| Metric | COYA | Rank |
|---|---|---|
| ROE | -50.1% | 29/38 |
| ROA | -45.8% | 38/43 |
| ROIC | -52.9% | 39/46 |
| Operating Margin | -288.7% | 36/39 |
| Net Margin | -270.2% | 32/35 |
| EBT Margin | -270.2% | 43/46 |
Financial Health
| Metric | COYA | Rank |
|---|---|---|
| Current Ratio | 13.40x | 12/59 |
| D/E Ratio | 0.09x | 39/48 |
| Financial Leverage | 1.09x | 40/48 |
| Working Capital | $44M | 53/59 |
Cash Flow
| Metric | COYA | Rank |
|---|---|---|
| Operating Cash Flow | -$16M | 37/59 |
Operational Efficiency
| Metric | COYA | Rank |
|---|---|---|
| Asset Turnover | 0.17x | 35/40 |
| Fixed Assets Turnover | 1428.4x | 2/41 |
Income Statement
| Metric | COYA | Rank |
|---|---|---|
| Total Revenue | $8M | 45/46 |
| Operating Income | -$23M | 29/51 |
| Net Income | -$22M | 25/46 |
| R&D Expense | $17M | 58/58 |
Dividend & Shareholder Information
| Metric | COYA | Rank |
|---|---|---|
| Shares Outstanding | 23M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $47M | 99.4% of assets |
| Cash & Short-term Investments | $43M | 91.2% of assets |
| Total Liabilities | $4M | 8.5% of assets |
| Short-term Debt | $2M | 5.1% of assets |
COYA quarterly financials and insider trading
Coya Therapeutics, Inc. (COYA) industry peers
Companies classified under the same SEC industry code as Coya Therapeutics, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| COYA Coya Therapeutics, Inc. | ▲ | $102M |
| LLY Eli Lilly & Co | ▼ | $1.18T |
| JNJ Johnson & Johnson | ▼ | $610.38B |
| ABBV Abbvie Inc. | ▼ | $500.75B |
| MRK Merck & Co., Inc. | ▶ | $358.21B |
| NVS Novartis Ag | ▼ | $286.95B |
| AZN Astrazeneca Plc | ▼ | $258.35B |
| ABT Abbott Laboratories | ▼ | $182.04B |
| NVO Novo Nordisk A S | ▼ | $174.29B |
| PFE Pfizer Inc | ▼ | $167.80B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $128.95B |
| BMY Bristol Myers Squibb Co | ▼ | $123.73B |
| SNY Sanofi | ▼ | $99.33B |
| GSK Gsk Plc | ▼ | $98.90B |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $82.34B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $60.76B |
| TEVA Teva Pharmaceutical Industries Ltd | ▼ | $47.91B |
| ONC Beone Medicines Ltd. | ▲ | $42.53B |
| ZTS Zoetis Inc. | ▼ | $32.40B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.32B |
| RPRX Royalty Pharma Plc | ▶ | $26.29B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.59B |
| GMAB Genmab A/S | ▶ | $24.33B |
| UTHR United Therapeutics Corp | ▼ | $23.23B |
| INSM Insmed Inc | ▶ | $21.67B |
| VTRS Viatris Inc | ▼ | $20.93B |
| ASND Ascendis Pharma A/S | ▲ | $14.94B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.92B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $13.12B |
| SMMT Summit Therapeutics Inc. | ▲ | $12.26B |
| CORT Corcept Therapeutics Inc | ▲ | $12.26B |
| ELAN Elanco Animal Health Inc | ▶ | $11.76B |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.85B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.77B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▼ | $10.62B |
| CYTK Cytokinetics Inc | ▲ | $8.89B |
| TGTX Tg Therapeutics, Inc. | ▶ | $8.89B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.84B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.47B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.26B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.33B |
| ABVX Abivax S.A. | ▼ | $7.26B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.06B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.93B |
| ALKS Alkermes Plc. | ▲ | $6.73B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▼ | $6.24B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.15B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▲ | $6.06B |
| BLTE Belite Bio, Inc | ▲ | $6.00B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $5.95B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.35B |
| ERAS Erasca, Inc. | ▲ | $5.20B |
| COGT Cogent Biosciences, Inc. | ▲ | $5.12B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.09B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $4.89B |
| MANE Veradermics, Inc | ▲ | $4.81B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.72B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.17B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.15B |
| INDV Indivior Pharmaceuticals, Inc. | ▼ | $3.97B |
Where COYA sits on the market map
Coya Therapeutics, Inc. (COYA) stock news
Loading...
Coya Therapeutics, Inc. (COYA) stock forecast FAQ
What is the Coya Therapeutics, Inc. (COYA) stock forecast?
Our AI ranks Coya Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Coya Therapeutics, Inc. stock predictions?
For COYA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 2.0%, measured on 322 forecast dates between 2023-03-31 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 5.0%, measured on 365 forecast dates between 2023-03-31 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Coya Therapeutics, Inc. forecasts updated?
Coya Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Coya Therapeutics, Inc.'s industry peers?
60 issuers in our coverage, COYA included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.